SUBSCRIBE
SUBSCRIBE
News   Business

GlaxoSmithKline Scraps Synta Pharmaceuticals Deal After Drug Disappoints

June 15, 2009 | 
1 min read

Bookmark and Share

Reuters -- GlaxoSmithKline has ended a collaboration with U.S. biotech company Synta following the suspension of clinical trials on an experimental skin cancer drug they were developing.

Alliances
GlaxoSmithKline
MORE ON THIS TOPIC
AbbVie's office in South San Francisco, California
Obesity
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative background
Deals
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal
February 28, 2025
 · 
2 min read
 · 
Annalee Armstrong
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
February 28, 2025
 · 
1 min read
 · 
Angela Gabriel
Pictured: Eli Lilly's headquarters in Indianapolis
Collaboration
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac